It has been a roller coaster 2020 so far for nano-cap biotech Iterum Therapeutics (ITRM). Over the past two trading sessions, ITRM shares surged nearly 85% after a regulatory path was outlined for the ...

A downtrend has been apparent in Iterum Therapeutics PLC (ITRM) lately with too much selling pressure. The stock has declined 67.8% over the past four weeks. However, given the fact that it is now in ...

Iterum Therapeutics Plc (NASDAQ:ITRM), an infectious disease biopharma company preparing to launch a new oral antibiotic for urinary tract infections, reported its results for the second quarter of ...

The average one-year price target for Iterum Therapeutics (NasdaqCM:ITRM) has been revised to 6.63 / share. This is an increase of 550.00% from the prior estimate of 1.02 dated December 13, 2021. The ...

On Friday, Iterum Therapeutics plc (NASDAQ:ITRM) received FDA approval for its Orlynvah (sulopenem etzadroxil and probenecid) for uncomplicated urinary tract infections (uUTIs) caused by the ...

Iterum Therapeutics (NASDAQ:ITRM) stock is taking off on Monday as investors react to news of a clinical trial agreement with the U.S. Food and Drug Administration (FDA). This agreement has to do with ...

) has been revised to $9.18 / share. This is an increase of 63.64% from the prior estimate of $5.61 dated February 21, 2026. The price target is an average of many targets provided by analysts. The ...

--ORLYNVAHTM Approved by FDA in Q4 2024— --Extended Cash Runway-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc ...

ITRM stock is experiencing heavy trading today to go with its increase in price. That’s seen some 133 million shares of the stock change hands as of this writing. To put that in perspective, the ...

A downtrend has been apparent in Iterum Therapeutics PLC (ITRM) lately with too much selling pressure. The stock has declined 67.8% over the past four weeks. However, given the fact that it is now in ...

Non-GAAP EPS was ($0.13), missing the consensus estimate by $0.02 (non-GAAP), due to higher pre-commercialization spending. Research and development expenses fell 48.2% compared to Q2 2024, while ...